Investigators analyzed claims data to evaluate whether adding a neurokinin-1 receptor antagonist to standard dexamethasone-containing antiemetic regimens altered the short-term incidence of new-onset diabetes in patients receiving chemotherapy. The study team reported a statistically significant association: patients who received both NK1-RA and dexamethasone had higher odds of developing new diagnostic codes for diabetes or receiving antidiabetic prescriptions within the predefined follow-up window. The adjusted odds ratio reported by the authors was 1.43 with a 95% confidence interval of 1.31–1.55 (p < 0.001), indicating a 43% relative increase in odds in this claims-based analysis.
The authors used the DeSC health claims database and included adults aged 18 years or older with solid tumors who started parenteral anticancer therapy and dexamethasone between April 2014 and March 2023. Patients with a prior history of diabetes or with hematologic malignancies were excluded from the analysis. The primary outcome, new-onset diabetes, was defined by either International Classification of Diseases, Tenth Revision (ICD-10) diagnostic codes consistent with diabetes or by initiation of antidiabetic medication prescriptions during the two months following the index month. The source did not provide laboratory confirmation such as fasting glucose or HbA1c values; outcome ascertainment relied on claims diagnostic and prescription records.
Among 71,539 eligible patients, the study team observed that 51.1% received an NK1-RA in combination with dexamethasone. Multivariable logistic regression models adjusted for relevant covariates (as documented by the authors) produced the reported adjusted odds ratio of 1.43 for the association between NK1-RA co-administration and new-onset diabetes. The authors performed sensitivity analyses that changed the evaluation periods and outcome definitions; these analyses reportedly produced consistent findings, reinforcing the primary signal within the constraints of claims-based research.
Data indicated an association but did not establish causation. The authors suggested that the combination of NK1-RA and systemic corticosteroid exposure could plausibly increase hyperglycemia risk compared with dexamethasone exposure alone, given known metabolic effects of corticosteroids. However, the claims database did not include dosing details, daily corticosteroid exposure, cumulative steroid dose, or timing of NK1-RA administration relative to dexamethasone—details the source did not report—so mechanistic attribution remains speculative within the limits of the dataset. The study authors framed the signal as a safety concern that merits attention when managing antiemetic regimens alongside steroid use, consistent with recommendations in many clinical guidelines to consider steroid-sparing strategies when appropriate.
The report is a retrospective cross-sectional study using health claims, and the authors acknowledged inherent limitations to this design. Claims data lack direct laboratory measures, so the outcome definition depended on diagnostic coding and prescription capture rather than biochemical confirmation. The source did not report specific dexamethasone dosing schedules, NK1-RA agents by name or dose, or patient-level glycemic metrics. Residual confounding is possible despite multivariable adjustment; temporal or unmeasured clinical factors could contribute to the observed association.
Key unanswered questions that the authors left open include whether the association persists after accounting for corticosteroid dose intensity and duration, whether particular NK1-RA agents differ in effect, and whether biochemical hyperglycemia without diagnostic coding was underestimated. The ethics committee at Tokyo University of Pharmacy and Life Sciences approved the study (approval number: 2025–033). The authors declared no competing interests.
Clinical teams should interpret the reported association with caution. The study identifies a claims-based safety signal: co-administration of NK1-RA and dexamethasone correlated with higher odds of claims-defined new-onset diabetes in this Japanese cohort. Prospective studies with laboratory endpoints, dose-level exposure data, and longer follow-up are required to clarify causality, quantify absolute risk, and guide specific changes to antiemetic or steroid management in oncology practice.